Aptose Biosciences Inc. (APTO)

NASDAQ: APTO · IEX Real-Time Price · USD
1.660
+0.160 (10.67%)
Mar 28, 2024, 2:48 PM EDT - Market open

Company Description

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States.

Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and Tuspetinib, an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML.

The company also develops luxeptinib, an orally administered, and potent dual lymphoid and myeloid kinome inhibitor that is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS.

It has agreements with CrystalGenomics, Inc. and Hanmi Pharmaceutical Co. Ltd. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014.

Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Aptose Biosciences Inc.
Aptose Biosciences logo
Country Canada
Founded 1986
Industry Biotechnology
Sector Healthcare
Employees 35
CEO Dr. William G. Rice Ph.D.

Contact Details

Address:
251 Consumers Road, Suite 1105
Toronto, A6 M2J 4R3
Ontario, Canada
Phone 647-479-9828
Website aptose.com

Stock Details

Ticker Symbol APTO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000882361
CUSIP Number 03835T200
ISIN Number CA03835T3091
SIC Code 2836

Key Executives

Name Position
Dr. William G. Rice Ph.D. Chairman, President, Chief Executive Officer and Chief Accounting Officer
Fletcher Payne Senior Vice President, Chief Financial Officer, Chief Business Officer and Secretary
Dr. Rafael Bejar M.D., Ph.D. Senior Vice President and Chief Medical Officer
Dr. Marc Wiles Ph.D. Senior Vice President of Regulatory Affairs
Brooks Ensign M.B.A. Vice President and Controller

Latest SEC Filings

Date Type Title
Mar 26, 2024 10-K Annual Report
Mar 26, 2024 8-K Current Report
Mar 18, 2024 8-K Current Report
Mar 1, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 5, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Jan 31, 2024 8-K Current Report
Jan 30, 2024 8-K Current Report
Jan 26, 2024 424B4 Prospectus
Jan 26, 2024 8-K Current Report